Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24999225 | 1.00 | MAOA (0.41) | MAOAMAOBNISCHHTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL27782030 | 0.98 | MAOA (0.40) | MAOAMAOBNISCHHTR2ASLC6A2 | |
| SCHEMBL23377295 | 0.98 | MAOA (0.40) | MAOAMAOBNISCHHTR2ASLC6A2 | |
| SCHEMBL7343966 | 0.78 | ALDH1A1 (0.44) | MAOAMAOBHTR2ACYP2D6RAB9A | |
| SCHEMBL30587236 | 0.78 | ALDH1A1 (0.44) | MAOAMAOBHTR2ACYP2D6RAB9A | |
| SCHEMBL16534913 | 0.78 | HSD17B10 (0.41) | MAOAMAOBSMN1; SMN2LMNA | |
| SCHEMBL27415175 | 0.76 | HTR2A (0.39) | NISCHHTR2ASLC6A2CYP2D6SLC6A4 | |
| SCHEMBL19810459 | 0.75 | SLC6A2 (0.38) | MAOAMAOBNISCHSLC6A2CYP2D6 | |
| SCHEMBL11419089 | 0.73 | SLC6A2 (0.37) | NISCHHTR2ASLC6A2CYP2D6SLC6A4 | |
| SCHEMBL22731139 | 0.73 | HTR2A (0.37) | NISCHHTR2ASLC6A2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| CN-114989417-A | Alkyl-polyphenol 2D Janus nanosheet and Pickering emulsion as well as preparation method and application thereof | 石河子大学 | 2022-09-02 | — | — | CN | claimed |
| CN-113122062-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-9944663-B2 | Process for preparing substituted pentacenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2018-04-17 | — | — | US | claimed |
| US-20120305854-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-06 | — | — | US | claimed |
| US-8318048-B2 | Process for preparing substituted pentacenes | MERCK PATENT GMBH (DE) | 2012-11-27 | — | — | US | claimed |
| EP-2134725-B1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2012-07-04 | — | — | EP | claimed |
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | MERCK PATENT GMBH (DE) | 2010-05-27 | — | — | US | claimed |
| EP-2134725-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | Merck Patent GmbH (DE) | 2009-12-23 | — | — | EP | claimed |
| WO-2008128618-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | MERCK PATENT GMBH (DE) | 2008-10-30 | — | — | WO | claimed |
| EP-4296365-A2 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | Visolis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3224368-B1 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID | VISOLIS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230045245-A1 | HETEROCYCLIC COMPOUND OR SALT THEREOF, ACTIVE MATERIAL, ELECTROLYTIC SOLUTION AND REDOX FLOW BATTERY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-02-09 | — | — | US | disclosed |
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| CN-115215995-A | Phosphorus-nitrogen-containing hindered phenol-based flame retardant and preparation method and application thereof | 东莞理工学院 | 2022-10-21 | — | — | CN | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0022875-B1 | PRESSURE-SENSITIVE RECORDING MATERIAL | MISHIMA PAPER CO. LTD (JP) | 1985-03-13 | — | — | EP | disclosed |
| US-4339143-A | Pressure-sensitive recording material | MISHIMA PAPER CO., LTD. (JP) | 1982-07-13 | — | — | US | disclosed |
| EP-0022875-A1 | PRESSURE-SENSITIVE RECORDING MATERIAL | MISHIMA PAPER CO. LTD (JP) | 1981-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127220-A1 | Process for Preparing Substituted Pentacenes | FES, PFAS, SLC46A1 | MAOA 2348/4885MAOB 3180/4885NISCH 1047/4885 |
| US-20120305854-A1 | PROCESS FOR PREPARING SUBSTITUTED PENTACENES | FES, PFAS, SLC46A1 | MAOA 2348/4885MAOB 3180/4885NISCH 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.